



# Does Spore Count Matter in Fungal Allergy?: The Role of Allergenic Fungal Species

Wan-Rou Lin,<sup>1</sup> Yi-Hsing Chen,<sup>2,3\*</sup> Mey-Fann Lee,<sup>4</sup> Ling-Yi Hsu,<sup>5</sup> Chih-Jen Tien,<sup>1</sup> Feng-Ming Shih,<sup>1</sup> Shih-Ching Hsiao,<sup>1</sup> Pi-Han Wang<sup>1\*</sup>

<sup>1</sup>Department of Life Science, Tunghai University, Taichung, Taiwan

<sup>2</sup>Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, Taichung, Taiwan

<sup>3</sup>Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan

<sup>4</sup>Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan

<sup>5</sup>The Environmental Analysis Laboratory, Taoyuan, Taiwan

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Purpose:** Fungi have been known to be important aeroallergens for hundreds of years. Most studies have focused on total fungal concentration; however, the concentration of specific allergenic fungi may be more important on an individual basis. **Methods:** Ten fungal allergic patients and 2 non-fungal allergic patients were enrolled. The patients with a decrease in physician or patient global assessment by more than 50% of their personal best were considered to have an exacerbation of allergic symptoms and to be in the active stage. Those who maintained their physician and patient global assessment scores at their personal best for more than 3 months were considered to be in the inactive stage. The concentrations of dominant fungi in the patients' houses and outdoors were measured by direct and viable counts at active and inactive stages. **Results:** The exacerbation of allergic symptoms was not correlated with total fungal spore concentration or the indoor/outdoor ratio (I/O). Specific fungi, such as *Cladosporium oxysporum* (*C. oxysporum*), *C. cladosporioides*, and *Aspergillus niger* (*A. niger*), were found to be significantly higher concentrations in the active stage than in the inactive stage. Presumed allergenic spore concentration threshold levels were 100 CFU/m<sup>3</sup> for *C. oxysporum*, and 10 CFU/m<sup>3</sup> for *A. niger*, *Penicillium brevicompactum* and *Penicillium oxalicum*. **Conclusions:** The major factor causing exacerbation of allergic symptoms in established fungal allergic patients may be the spore concentration of specific allergenic fungi rather than the total fungal concentration. These results may be useful in making recommendations as regards environmental control for fungal allergic patients.

**Key Words:** Fungal allergy; spore count; threshold level; airborne fungal spore; I/O ratio; household

## INTRODUCTION

Fungi are ubiquitous in the environment, and their spores are found widely in the air. As early as the 12th century, fungi were recognized as aeroallergens. Living in a damp or moldy environment has been reported to be associated with an increased risk of developing asthma, allergic rhinitis/sinusitis and atopic dermatitis as well as increasing severity of allergic diseases.<sup>1-13</sup>

The prevalence of fungal allergy varies from 10%-80% among patients with allergic airway diseases and atopic dermatitis in different regions.<sup>5,14-16</sup> More than 180 fungal species have been reported to induce IgE-mediated hypersensitivity in susceptible persons, among which Ascomycota (*Alternaria*, *Aspergillus*, *Bipolaris*, *Candida*, *Cladosporium*, *Epicoccum*, and *Phoma*) and Basidiomycota (*Calvatia*, *Coprinus*, *Ganoderma*, *Pleurotus*, and *Psilocybe*) phyla are considered to be of greater clinical importance.<sup>11,17-19</sup>

Previous studies using the gravity slide method have shown that the most predominant airborne fungi in Taiwan are *Cladosporium* species, followed by *Ganoderma*, *Aspergillus*, and *Fusarium* species.<sup>20</sup> The prevalence of sensitization to airborne fungi has been reported to be around 10% among patients with asthma<sup>21</sup> and 1.3%-9.3% among patients with allergic rhinitis in Taiwan.<sup>21-23</sup>

**Correspondence to:** Pi-Han Wang, PhD, Department of Life Science, Tunghai University, 1727 Taiwan Boulevard, Section 4, Taichung, 40704, Taiwan. Tel:+886-4-23590121; Fax:+886-4-23590296; E-mail: phwang@thu.edu.tw

Yi-Hsing Chen, MD PhD, Division of Allergy, Immunology and Rheumatology, Taichung Veterans General Hospital, 650 Taiwan Boulevard, Section 4, Taichung, 40704, Taiwan.

Tel: +886-4-23592525; Fax: +886-4-23503285; E-mail: ysanne@vghtc.gov.tw  
Received: May 3, 2015; Revised: July 26, 2015; Accepted: January 26, 2016

• There are no financial or other issues that might lead to conflict of interest.

Increasing evidence has shown positive associations of indoor dampness or the presence of fungi with the development and exacerbation of asthma as well as eczema and allergy. However, most published studies have involved qualitative assessments of dampness or fungi, such as moldy odor, visible water damage, or visible dampness,<sup>24</sup> and only a few studies have quantitatively measured levels of specific fungal spores or culturable fungi for individual patients.

The aim of this study was to investigate the levels of fungal spores and culturable fungi in the houses of fungal allergic patients in central Taiwan during inactive and exacerbation (active) stages.

## MATERIALS AND METHODS

### Patient selection

Ten fungal allergic patients and 2 non-fungal allergic patients who were regularly followed up in the Allergy Clinic of Taichung Veteran's General Hospital, were recruited either by invitation of their physician (Y.H.C.) or by responding voluntarily to an advertisement. The levels of specific immunoglobulin E antibodies (IgE) to common inhaled allergens were analyzed using an ImmunoCAP System™ (Phadia AB, Uppsala, Sweden). A specific IgE level  $\geq 0.35$  kU/L was defined as a positive reaction according to the manufacturer's instructions.<sup>24</sup> This study was approved by the Institutional Review Board of Taichung Veterans General Hospital (IRB No: CE11245).

Patients with a decrease in physician or patient global assessment using the visual analogue scale by more than 50% of their personal best were considered to have an exacerbation of allergic symptoms and to be in the active stage. Patients who maintained their physician and patient global assessment scores at their personal best for more than 3 months were considered to be in the inactive stage.

### Environmental sample collection

From April 2012 to October 2013, air samples from the patient's bedrooms and an additional most commonly used rooms as well as the courtyards of the patient's house during active and inactive stages were collected using an air sampler (Coriolis®, Bertin, France) with a high flow rate of 300 L/min for viable spore collection.

In brief, 7.5 mL of 0.005% Triton-X100 was added to autoclaved sample bottles and then added every 10 minutes to maintain the volume at 7.5 mL, and the air velocity was set to 300 L/min for 30 minutes to allow for collection of an estimated total of 9 m<sup>3</sup> of suspended particles. All samples were stored at 4°C and sent to the laboratory as quickly as possible.

For indoor collection, the air sampler was placed in the center of the room, 120-150 cm above the ground and away from walls or corners by at least 50 cm. For outdoor collection, the air intake was faced into the prevailing wind, and people were pre-

vented from being upwind during collection. The power generator was set up at least 10 m downwind and away from the air sampler to exclude the effect of waste gas during outdoor collection.

### Airborne fungal sample counting and identification

All the collected samples were centrifuged at 13,000 rpm to 1 mL, and then direct counting and viable counting were used to calculate the total number of spores and concentrations of dominant culturable fungal spores. For the direct count, 10  $\mu$ L of the sample solution were added to a hemocytometer (Counting Chamber, Marienfeld, Germany) and were then counted under a microscope for total fungal spore concentration. Each sample was counted 3 times. For the viable count, samples were serially diluted with 0.005% Triton-X100 and then spread on 1/2 potato dextrose agar (PDA, Difco, Detroit, MI, USA). The plates were incubated at 25°C, and fungal colonies were counted after 3 to 5 days. Each assessment was performed in triplicate. The colonies were examined with a microscope to visually characterize and identify species.

Extraction of total DNA was performed on the mycelium of dominant fungal strains using the CTAB method reported by Doyle and Doyle.<sup>25</sup> The internal transcribed spacer (ITS) region of ribosomal DNA (rDNA) was amplified with the primers ITS5/4 or ITS1/4.<sup>26</sup> DNA sequencing was performed at Mission Biotech, Taiwan with the same primers. ITS sequences were used for molecular identification.

### Data analysis

Logistic regression analysis was used to analyze correlations between exacerbations of allergic symptoms and total or viable count using R software (R Foundation for Statistical Computing, Vienna, Austria). Changes in the viable count of potential allergic species between the active and inactive stages were estimated by calculating the number of spores and colonies in the target patients and analyzed using paired *t* tests with R software. Statistical significance was set at  $P < 0.05$ . In order to estimate the threshold levels of allergic fungi, we compared the viable count data of the target patients (a specific IgE level  $\geq 0.35$  kU/L and at least 1 colony in the active stage) during inactive and active stages. The threshold was reported at the highest level in the inactive stage.

## RESULTS

### Study subjects

Twelve subjects were enrolled in this study, including 10 fungal allergic patients and 2 non-fungal allergic patients as controls. The demographics of the study subjects are listed in Table 1. Among the 10 patients, 9 were allergic to *Penicillium notatum*, 7 to *Cladosporium herbarum* (*C. herbarum*), 8 to *Aspergillus fumigatus* (*A. fumigatus*), 9 to *Candida albicans*, and 5 to *Al-*

**Table 1.** Demographics of the study subjects

| No. | Sex | Age | Allergic diseases | <i>P. notatum</i> | <i>C. herbarum</i> * | <i>A. fumigatus</i> * | <i>C. albicans</i> * | <i>A. alternata</i> * | Mixed house dust mites* |
|-----|-----|-----|-------------------|-------------------|----------------------|-----------------------|----------------------|-----------------------|-------------------------|
| P1  | F   | 56  | A, AR             | 2.87              | 0.41                 | 6.59                  | —                    | 2.43                  | 0.51                    |
| P2  | F   | 30  | AR, AD            | 1.91              | 1.08                 | 3.94                  | 9.17                 | —                     | 74.2                    |
| P3  | F   | 25  | AR, AD            | —                 | —                    | 0.73                  | 1.29                 | —                     | 53.9                    |
| P4  | F   | 19  | AD                | 1.72              | 0.88                 | 0.77                  | 4.9                  | 0.48                  | >100                    |
| P5  | F   | 17  | AD                | 0.35              | —                    | —                     | 8.03                 | —                     | 0.78                    |
| P6  | F   | 30  | AR, AD            | 0.8               | 0.62                 | 2.88                  | 4.56                 | —                     | 74.2                    |
| P7  | M   | 28  | A, AR, AD         | 8.53              | 4.9                  | 16.5                  | 6.22                 | 27.1                  | 34.8                    |
| P8  | M   | 77  | A, AR             | 0.69              | —                    | —                     | 4.26                 | —                     | 1.72                    |
| P9  | M   | 46  | AR, AD            | 12.1              | 1.18                 | 1.47                  | 1.84                 | 0.7                   | 3.87                    |
| P10 | M   | 30  | AD                | 1.94              | 0.82                 | 1.05                  | 1.6                  | 0.44                  | >100                    |
| C1  | F   | 54  | A                 | —                 | —                    | —                     | —                    | —                     | 0.73                    |
| C2  | M   | 61  | AR                | —                 | —                    | —                     | —                    | —                     | 1.36                    |

“—” denotes data <0.35 kU/mL.

\*ImmunoCAP specific IgE to the designated allergen (kU/L).

A, asthma; AR, allergic rhinitis; AD, atopic dermatitis.

**Table 2.** I/O ratio in the subjects' houses during the active and inactive stages of allergy

| No. | Space* | Direct count (spores/m <sup>3</sup> ) |                 | Viable count (CFU/m <sup>3</sup> ) |             |
|-----|--------|---------------------------------------|-----------------|------------------------------------|-------------|
|     |        | Inactive                              | Active          | Inactive                           | Active      |
| P5  | r-1    | <b>0.44</b>                           | 0.62            | 0.70                               | 0.25        |
|     | r-2    | 0.73                                  | ND <sup>†</sup> | 0.71                               | 0.29        |
| P6  | r-1    | <b>0.63</b>                           | <b>0.98</b>     | <b>0.32</b>                        | <b>1.13</b> |
|     | r-2    | 1.13                                  | 0.78            | 0.86                               | 0.45        |
| P7  | r-1    | <b>0.69</b>                           | <b>0.92</b>     | 0.65                               | 0.50        |
|     | r-2    | 0.45                                  | 0.42            | 0.46                               | 0.23        |
| P8  | r-1    | 0.36                                  | 0.21            | 1.42                               | 0.57        |
|     | r-2    | 0.60                                  | 0.22            | 3.25                               | 0.15        |
| P9  | r-1    | <b>0.45</b>                           | <b>0.93</b>     | <b>0.17</b>                        | <b>0.84</b> |
|     | r-2    | <b>0.09</b>                           | <b>0.70</b>     | <b>0.06</b>                        | <b>0.59</b> |
| P10 | r-1    | <b>0.54</b>                           | <b>0.88</b>     | <b>0.71</b>                        | <b>1.00</b> |
|     | r-2    | <b>0.47</b>                           | <b>1.40</b>     | <b>0.43</b>                        | <b>0.48</b> |

Bold: the I/O ratio was bigger in the active stage than in the inactive stage.

\*r-1 and r-2 denote data from room 1 and room 2 of each subject; <sup>†</sup>ND denotes non-detectable.

*ternaria alternata* (*A. alternata*). P4, P7, P9, and P10 were allergic to all tested fungi.

### Fungal concentrations in the patient's rooms of the patients

The total fungal concentrations were estimated by total and viable counts in 2 rooms of the patient's houses. The mean total and viable counts indoors in the active stage ranged from non-detectable to  $4.52 \times 10^5$  spores/m<sup>3</sup> and non-detectable to  $1.01 \times 10^3$  CFU/m<sup>3</sup>, respectively compared to  $1.99 \times 10^3$  to  $2.75 \times 10^4$  spores/m<sup>3</sup> and 9.61 to 445.78 CFU/m<sup>3</sup> in the inactive stage, respectively (Fig. 1). Although the mean total and viable count

were higher in the active stage than in the inactive stage, the results of logistic regression showed that there was no significant association between exacerbations of allergic symptoms and total or viable count ( $P > 0.05$ , data not shown). The total and viable counts outdoors in the active stage ranged from  $3.93 \times 10^3$  to  $8.45 \times 10^4$  spores/m<sup>3</sup> and 131 to 725 CFU/m<sup>3</sup>, respectively compared to  $7.65 \times 10^3$  to  $3.87 \times 10^4$  spores/m<sup>3</sup> and 61 to 612 CFU/m<sup>3</sup> in the inactive stage, respectively (Fig. 1).


Table 2 shows the indoor/outdoor (I/O) ratio calculated from direct and viable counts. The I/O ratio could be bigger or smaller in the active stage than in the inactive stage, and there was no consistent pattern. Logistic regression analysis also showed no significant association between allergy and the I/O ratio ( $P = 0.693$ ), suggesting that the I/O ratio is not suitable for predicting the occurrence or exacerbation of allergy.

### Prevalence of fungal species

Table 3 lists the frequencies of occurrence of the fungal species. *Cladosporium* spp., *C. oxysporum*, *C. cladosporioides*, *Aspergillus* spp., *Penicillium oxalicum*, and *Penicillium* spp. were found most frequently during the active stage. However, the frequencies of occurrence during active and inactive stages were not significantly different.

### Stage variations in the concentrations of some fungal species

We then examined the effect of individual fungal concentrations on exacerbations of allergic symptoms (active stage) among different fungal allergens. The mean concentration of *C. oxysporum* among the target patients (P1, P2, P4, P6, P7, P9, and P10) during active and inactive stages ranged from 8.7 to 620.6 CFU/m<sup>3</sup> and 0.9 to 88.3 CFU/m<sup>3</sup>, respectively (Supplemental Table, Fig. 2A). For *Cladosporium cladosporioides* (*C. cladosporioides*), the mean concentration among the target pa-



**Fig. 1.** (A) Direct spore count in the subjects' houses during the active and inactive stages of allergy, (B) Viable count in the subjects' houses during the active and inactive stages of allergy. r-1 and r-2 denote mean spore counts in room 1 and room 2 for each patient. 0 denotes means of outdoor spore counts for each patient.


tients ranged from 0.9 to 157.3 CFU/m<sup>3</sup> in the active stage, and from non-detectable to 26.2 CFU/m<sup>3</sup> in the inactive stage (Supplemental Table, Fig. 2B). The indoor concentrations of *C. oxysporum* and *C. cladosporioides* were significantly higher during the active stage than during the inactive stage ( $P=0.03$  and  $0.04$ , respectively). There were also more *Cladosporium* spp. in the active stage than in the inactive stage ( $P=0.03$ ) (Fig. 2C). With regard to *Aspergillus niger*, the indoor concentrations were sig-

nificantly higher in the active stage than in the inactive stage ( $P=0.02$ ), with the mean concentration ranging from non-detectable to 35.0 CFU/m<sup>3</sup> during active stage and non-detectable to 12.2 CFU/m<sup>3</sup> during inactive stage (Supplemental Table, Fig. 2D). With regard to *Penicillium brevicompactum* (*P. brevicompactum*), the mean concentration ranged from non-detectable to 26.2 CFU/m<sup>3</sup> during the active stage, and non-detectable to 17.5 CFU/m<sup>3</sup> during the inactive stage (Supplemental Table,

**Table 3.** The frequency\* of fungal species in the patients' houses during the active and inactive stages

|                           | Target patients       |       |          |       | All subjects |       |          |       |
|---------------------------|-----------------------|-------|----------|-------|--------------|-------|----------|-------|
|                           | Active                |       | Inactive |       | Active       |       | Inactive |       |
|                           | With/all <sup>†</sup> | %     | With/all | %     | With/all     | %     | With/all | %     |
| <i>Cladosporium</i> spp.  | 7/7                   | 100.0 | 7/7      | 100.0 | 12/12        | 100.0 | 12/12    | 100.0 |
| <i>C. oxysporum</i>       | 7/7                   | 100.0 | 7/7      | 100.0 | 12/12        | 100.0 | 12/12    | 100.0 |
| <i>C. cladosporioides</i> | 7/7                   | 100.0 | 5/7      | 71.4  | 12/12        | 100.0 | 11/12    | 91.7  |
| <i>Aspergillus</i> spp.   | 6/8                   | 75.0  | 6/8      | 75.0  | 10/12        | 83.3  | 10/12    | 83.3  |
| <i>A. flavus</i>          | 2/8                   | 25.0  | 3/8      | 37.5  | 5/12         | 41.7  | 7/12     | 58.3  |
| <i>A. fumigatus</i>       | 2/8                   | 25.0  | 1/8      | 12.5  | 3/12         | 25.0  | 5/12     | 41.7  |
| <i>A. niger</i>           | 4/8                   | 50.0  | 5/8      | 62.5  | 6/12         | 50.0  | 10/12    | 83.3  |
| <i>Penicillium</i> spp.   | 7/9                   | 77.8  | 6/9      | 66.7  | 10/12        | 83.3  | 10/12    | 83.3  |
| <i>P. brevicompactum</i>  | 3/9                   | 33.3  | 1/9      | 11.1  | 4/12         | 33.3  | 2/12     | 16.7  |
| <i>P. oxalicum</i>        | 7/9                   | 77.8  | 6/9      | 66.7  | 11/12        | 91.7  | 10/12    | 83.3  |

\*The number of houses in which the fungal taxon was recorded out of the total number of houses sampled; <sup>†</sup>With/all denotes the number of houses with specific fungi all of the test houses.



**Fig. 2.** The Box-and-Whisker plot of fungal spore concentration (CFU/m<sup>3</sup>) in the active and inactive stages among patients with positive ImmunoCAP test results for specific IgE to the designated fungal allergens. (A) *Cladosporium oxysporum*, (B) *Cladosporium cladosporioides*, (C) *Cladosporium* spp., (D) *Aspergillus niger*, (E) *Penicillium brevicompactum*, and (F) *Penicillium oxalicum*.

Fig. 2E). For *Penicillium oxalicum* (*P. oxalicum*), the mean concentration ranged from non-detectable to 35 CFU/m<sup>3</sup> during the active stage, and non-detectable to 26.2 CFU/m<sup>3</sup> during the inactive stage (Supplemental Table, Fig. 2F). Differences in indoor concentrations of *P. brevicompactum* and *P. oxalicum* between active and inactive stages were not significant ( $P=0.05$  and 0.13, respectively). Because *A. flavus* and *A. fumigatus* were

only detected in 1 and 2 patients' houses, respectively, statistical analysis was not performed.

## DISCUSSION

There were several studies to emphasize total spore concentrations, which found the correlation between the high concen-

tration of total fungi and exacerbations of allergic symptoms.<sup>10,26-30</sup> We examined indoor total and specific allergenic fungal concentrations precisely in this study and found the importance of specific allergenic fungi in inducing exacerbation rather than total fungal concentration in triggering or exacerbating allergic symptoms among sensitized individuals. No association between total fungal counts and the occurrence of allergy was due to samples with lower fungal concentrations in the active stage than in the inactive stage. In P1 patient's house, for example the viable counts were 288 and 437 CFU/m<sup>3</sup> in active and inactive stages, respectively. In inactive stage, there were higher total fungal concentrations but lower concentrations of allergenic fungi *C. cladosporioides* and *C. oxysporum*, and no *A. niger* or *P. brevicompactum* was detected. This kind of samples showed associations between total fungal concentration and occurrence of allergy, which did not reach statistical significance. Ross *et al.*<sup>31</sup> reported that patients reporting visits to the emergency department were associated with total fungal concentration, although the statistical test result was not significant. The allergenic fungi ratio in total fungal concentration needs to be considered.

Recent studies reported that concentrations of *Alternaria*, *Penicillium*, and *Cladosporium* are correlated with infant wheezing<sup>27</sup> and the development of rhinitis in later life.<sup>28</sup> However, some reported that no association could be found between the spore concentration of these fungal genera in indoor air and asthma/allergy in children.<sup>32</sup> A recent meta-analysis of 7 studies demonstrated that the increased exacerbation of the asthma symptoms were significantly associated with increased level of specific fungal genera *Cladosporium* and *Alternaria* and that there was no association between exposure to *Penicillium/Aspergillus* and asthma.<sup>33</sup> Several species of *Aspergillus*, *Penicillium*, and *Cladosporium* have been shown to be allergenic, but not all species in these genera were allergenic fungi. If they analyzed the allergenic species of these genera only, the resolution could have been improved.

The study subjects in this study showed their heterogeneity in allergenic fungal species. To study the roles of specific allergenic fungi, it is important to include patients with a positive reaction of specific IgE level to each fungus. This is the first field study to examine indoor fungi concentrations and species precisely and to report the threshold value of allergenic fungi.

Our results showed that the concentrations of specific allergenic fungi, including *C. oxysporum*, *C. cladosporioides*, *A. niger*, and *P. brevicompactum*, were significantly higher in the active stage than in the inactive stage. The exacerbation of allergic symptoms may have been correlated with increases in these specific fungal concentrations, which is consistent with recent studies reporting that the concentrations of indoor and outdoor levels of *Alternaria*, *Penicillium*, and *Cladosporium* are correlated with infant wheezing<sup>27</sup> and the development of rhinitis in later life.<sup>28</sup>

According to individual fungal concentrations in active and inactive stages, we calculated the presumed threshold levels in the target patients (those with a positive fungal-specific IgE to that fungal allergen). The highest viable count of fungi during the inactive stage at the patient's house was presumed to be the threshold level for the exacerbation of allergic symptoms associated with that fungus. Based on these criteria, the threshold of *C. oxysporum* concentration was estimated to be 10<sup>2</sup> CFU/m<sup>3</sup>. In comparison, the concentration of *C. cladosporioides* during the inactive stage at the patients' houses was much lower, ranging from non-detectable to 26.2 CFU/m<sup>3</sup>. The proportion of *C. cladosporioides* in the total concentration of *Cladosporium* spp. was less than 35%. Therefore, the exacerbations may have been caused by the additive effects of *C. oxysporum* and *C. cladosporioides*. It is possible that *C. oxysporum* and *C. cladosporioides* share similar antigens, although further studies are required to investigate the degree of protein homology between the 2 *Cladosporium* species.

For *A. niger*, a threshold level of 10 CFU/m<sup>3</sup> was estimated. Although the difference in indoor concentration of *P. brevicompactum* was close to significance, we also estimated a threshold level of 10 CFU/m<sup>3</sup>. The viable count of *P. oxalicum* in the active stage was as high as that in the inactive stage (Fig. 2F). The threshold of *P. oxalicum* was not estimated in this study.

The high variations in the I/O ratio may be due to differences in building structure, air exchange rates, and seasonal variations in outdoor spores.<sup>29</sup> Thus, it is difficult to clarify the sources of allergenic fungi only by the I/O ratio. Using our presumed threshold levels, the allergenic fungi that caused the symptoms during the active stage were able to be determined in each patient. For example, patient P6 was sensitive to *P. notatum*, *C. herbarum*, and *A. fumigatus*. However, only the concentrations of *P. brevicompactum* and *P. oxalicum* in his house reached the threshold level and were higher in the active stage. Therefore, we inferred that *P. brevicompactum* and *P. oxalicum* caused the exacerbations in this patient. In the active stage of patient P6, the concentration of *P. brevicompactum* was 8.74 CFU/m<sup>3</sup> indoors and 0.87 CFU/m<sup>3</sup> outdoors, suggesting that the increase in *P. brevicompactum* was due to the indoor environment. In this context, the I/O ratio of *P. oxalicum* in patient P6's house was more than 1, indicating that the increase in these *Penicillium* species was due to the indoor environment. The exacerbation of allergic symptoms in patient P9 may have resulted from the increases in indoor concentrations of *P. oxalicum* and *A. niger*. This estimation may be helpful in making a correct diagnosis and recommendations for environmental control for fungal allergic patients.

*Cladosporium herbarum* is common in temperate zones.<sup>30,34-36</sup> Approximately 60 antigens from *C. herbarum* have been identified, of which at least 36 have been shown to react with IgE antibodies from patients' sera and have been used for allergen-specific IgE assays in commercial diagnostic kits. A previous

study showed that only 6% of 579 Taiwanese asthmatic patients had specific IgE to *C. herbarum*.<sup>37</sup> We did not find the spores of *C. herbarum* in the households of any of our patients, and only *C. oxysporum* and *C. cladosporioides* were found with *C. oxysporum* being predominant. As Taiwan is located in a subtropical area, *C. herbarum* may not be the main allergic fungus. The use of appropriate diagnostic IgE antibodies for a tropical area is therefore needed.

It has been reported that in addition to fungal spores, the large fragments of fungi, such as airborne fungal hyphae, may also play a role in fungal allergy.<sup>38</sup> However, the viable count method that we used to evaluate the amount of fungi could detect both active fungal spores and hyphae.

There are several limitations to this study. First, as the sample size is small in our study, the presumable threshold levels that we proposed in the above-mentioned discussion section may require a larger scale of study to confirm. Secondly, all the study patients were allergic to house dust mites. As we did not measure the concentrations of house dust mites in the patient's house, further studies are needed to elucidate whether there would be associations a reaction between the concentrations of house dust mites and fungi. In addition, most of our fungal allergic patients had both airway and skin allergies, and further studies are also needed to elucidate whether the influence of fungal concentrations on different allergic diseases are of equal importance. *Alternaria* is one of the important allergens, and because of the large spore size (23-34×7-10 μm), it is frequently found in house dust. As we focused on allergic fungi suspended in the air, the levels of dustborne fungi, such as *Alternaria*, may have been underestimated in this study.

In conclusion, our results showed that the concentrations of allergic fungi were correlated with disease exacerbations among fungal allergic patients, but total fungal spore concentration was not. The threshold levels of fungal concentration differed among species. The concentrations of *Cladosporium*, *Aspergillus* and *Penicillium* above threshold levels may be correlated with acute exacerbations of allergic symptoms in fungal allergic patients in Taiwan. These results may be useful in making a diagnosis and recommendations for environmental control for fungal allergic patients.

## ACKNOWLEDGMENTS

The study was funded by the Environmental Analysis Laboratory (EPA-101-E3S5-02-02, EPA-102-E3S5-02-02), Environmental Protection Administration, Executive Yuan, Taiwan.

## REFERENCES

1. Twaroch TE, Curin M, Valenta R, Swoboda I. Mold allergens in respiratory allergy: from structure to therapy. *Allergy Asthma Immunol Res* 2015;7:205-20.
2. Tischer CG, Hohmann C, Thiering E, Herbarth O, Müller A, Henderson J, et al. Meta-analysis of mould and dampness exposure on asthma and allergy in eight European birth cohorts: an ENRIECO initiative. *Allergy* 2011;66:1570-9.
3. Tischer C, Chen CM, Heinrich J. Association between domestic mould and mould components, and asthma and allergy in children: a systematic review. *Eur Respir J* 2011;38:812-24.
4. Pant H, Schembri MA, Wormald PJ, Macardle PJ. IgE-mediated fungal allergy in allergic fungal sinusitis. *Laryngoscope* 2009;119:1046-52.
5. Simon-Nobbe B, Denk U, Pöll V, Rid R, Breitenbach M. The spectrum of fungal allergy. *Int Arch Allergy Immunol* 2008;145:58-86.
6. Orman A, Fiçici SE, Ay A, Ellidokuz H, Sivaci RG, Konuk M. Detection of fungi spectrum in industrial and home bakeries and determined fungal allergy with skin prick test. *Asian Pac J Allergy Immunol* 2005; 23:79-85.
7. Zauli D, Grassi A, Vukatana G, Ballardini G, Bianchi FB. Allergy to fungal allergens in northern Italy. *Ann Allergy Asthma Immunol* 2004;92:92.
8. Kanny G, Becker S, de Hauteclouque C, Moneret-Vautrin DA. Airborne eczema due to mould allergy. *Contact Dermatitis* 1996;35:378.
9. Müller A, Lehmann I, Seiffart A, Diez U, Wetzig H, Borte M, et al. Increased incidence of allergic sensitisation and respiratory diseases due to mould exposure: results of the Leipzig Allergy Risk children Study (LARS). *Int J Hyg Environ Health* 2002;204:363-5.
10. Denning DW, Pashley C, Hartl D, Wardlaw A, Godet C, Del Giacco S, et al. Fungal allergy in asthma-state of the art and research needs. *Clin Transl Allergy* 2014;4:14.
11. Cramer R, Garbani M, Rhyner C, Huitema C. Fungi: the neglected allergenic sources. *Allergy* 2014;69:176-85.
12. Ogawa H, Fujimura M, Ohkura N, Makimura K. Atopic cough and fungal allergy. *J Thorac Dis* 2014;6:S689-98.
13. Shin SH, Ye MK, Kim JK. Effects of fungi and eosinophils on mucin gene expression in rhinovirus-infected nasal epithelial cells. *Allergy Asthma Immunol Res* 2014;6:149-55.
14. Bush RK, Portnoy JM, Saxon A, Terr AI, Wood RA. The medical effects of mold exposure. *J Allergy Clin Immunol* 2006;117:326-33.
15. Chang FY, Lee JH, Yang YH, Yu HH, Wang LC, Lin YT, et al. Analysis of the serum levels of fungi-specific immunoglobulin E in patients with allergic diseases. *Int Arch Allergy Immunol* 2011;154:49-56.
16. Beezhold DH, Green BJ, Blachere FM, Schmechel D, Weissman DN, Velickoff D, et al. Prevalence of allergic sensitization to indoor fungi in West Virginia. *Allergy Asthma Proc* 2008;29:29-34.
17. Vijay HM, Kurup VP. Fungal allergens. *Clin Allergy Immunol* 2008; 21:141-60.
18. Zukiewicz-Sobczak WA. The role of fungi in allergic diseases. *Postepy Dermatol Alergol* 2013;30:42-5.
19. Burge HA. Fungus allergens. *Clin Rev Allergy* 1985;3:319-29.
20. Su HJ, Wu PC, Chen HL, Lee FC, Lin LL. Exposure assessment of indoor allergens, endotoxin, and airborne fungi for homes in southern Taiwan. *Environ Res* 2001;85:135-44.
21. Tsai JJ, Chen WC. Different age of asthmatic patients affected by different aeroallergens. *J Microbiol Immunol Infect* 1999;32:283-8.
22. Liang KL, Su MC, Jiang RS. Comparison of the skin test and ImmunoCAP system in the evaluation of mold allergy. *J Chin Med Assoc* 2006;69:3-6.
23. Huang HW, Lue KH, Wong RH, Sun HL, Sheu JN, Lu KH. Distribution of allergens in children with different atopic disorders in central Taiwan. *Acta Paediatr Taiwan* 2006;47:127-34.

24. Mendell MJ, Mirer AG, Cheung K, Tong M, Douwes J. Respiratory and allergic health effects of dampness, mold, and dampness-related agents: a review of the epidemiologic evidence. *Environ Health Perspect* 2011;119:748-56.
25. Doyle JJ, Doyle JL. Isolation of plant DNA from fresh tissue. *Focus* 1990;12:13-5.
26. White TJ, Bruns T, Lee S, Taylor J. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DA, Sninsky JJ, White TJ, editors. *PCR protocols: a guide to methods and applications*. San Diego (CA): Academic Press; 1990. 315-22.
27. Behbod B, Sordillo JE, Hoffman EB, Datta S, Muilenberg ML, Scott JA, et al. Wheeze in infancy: protection associated with yeasts in house dust contrasts with increased risk associated with yeasts in indoor air and other fungal taxa. *Allergy* 2013;68:1410-8.
28. Behbod B, Sordillo JE, Hoffman EB, Datta S, Webb TE, Kwan DL, et al. Asthma and allergy development: contrasting influences of yeasts and other fungal exposures. *Clin Exp Allergy* 2015;45:154-63.
29. Chen C, Zhao B. Review of relationship between indoor and outdoor particles: I/O ratio, infiltration factor and penetration factor. *Atmos Environ* 2011;45:275-88.
30. Şakiyan N, İnceoğlu Ö. Atmospheric concentrations of *Cladosporium* and *Alternaria* spores in Ankara and the effects of meteorological factors. *Turk J Bot* 2003;27:77-81.
31. Ross MA, Curtis L, Scheff PA, Hryhorczuk DO, Ramakrishnan V, Wadden RA, et al. Association of asthma symptoms and severity with indoor bioaerosols. *Allergy* 2000;55:705-11.
32. Holme J, Hägerhed-Engman L, Mattsson J, Sundell J, Bornehag CG. Culturable mold in indoor air and its association with moisture-related problems and asthma and allergy among Swedish children. *Indoor air* 2010;20:329-40.
33. Sharpe RA, Bearman N, Thornton CR, Husk K, Osborne NJ. Indoor fungal diversity and asthma: A meta-analysis and systematic review of risk factors. *J Allergy Clin Immunol* 2015;135:110-22.
34. Kasprzyk I, Worek M. Airborne fungal spores in urban and rural environments in Poland. *Aerobiologia* 2006;22:169-76.
35. O'Gorman CM, Fuller HT. Prevalence of culturable airborne spores of selected allergenic and pathogenic fungi in outdoor air. *Atmos Environ* 2008;42:4355-68.
36. Oliveira M, Ribeiro H, Delgado JL, Abreu I. The effects of meteorological factors on airborne fungal spore concentration in two areas differing in urbanisation level. *Int J Biometeorol* 2009;53:61-73.
37. Chiang CH, Wu KM, Wu CP, Yan HC, Perng WC. Evaluation of risk factors for asthma in Taipei City. *J Chin Med Assoc* 2005;68:204-9.
38. Green BJ, Tovey ER, Sercombe JK, Blachere FM, Beezhold DH, Schmechel D. Airborne fungal fragments and allergenicity. *Med Mycol* 2006;44 Suppl 1:S245-55.